The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
- 1 August 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 378 (9792), 676-683
- https://doi.org/10.1016/s0140-6736(11)61126-4
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Effect of Cardiac Resynchronization Therapy on Reverse Remodeling and Relation to OutcomeCirculation, 2010
- Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart FailureCirculation: Heart Failure, 2010
- Systolic Heart FailureThe New England Journal of Medicine, 2010
- Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure EventsThe New England Journal of Medicine, 2009
- Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2consumption in dogsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Sarcomeric proteins and inherited cardiomyopathiesCardiovascular Research, 2007
- The Failing Heart — An Engine Out of FuelThe New England Journal of Medicine, 2007
- The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart FailureThe New England Journal of Medicine, 2005
- Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial InfarctionCirculation, 2004
- A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart FailureThe New England Journal of Medicine, 1998